The IL-23 inhibitor from AbbVie indicated for the treatment of moderately to severely active Crohn's disease (CD) in adults.1

RELIABLE DOSING SCHEDULE
AND THE OPTION TO
SELF-ADMINISTER AFTER TRAINING

RELIABLE DOSING SCHEDULE

SC Injection every 8 Weeks at Home or in the Office After 3 IV Infusions1

INDUCTION

3 IV Infusions

(600 mg per dose)

INDUCTION: 3 IV Infusions Week 0, 4 and 8

Administer each dose of SKYRIZI
over at least 1 hour

NDC Code: 0‍0‍7‍4‍-‍5‍0‍1‍5‍-‍0‍1 (Carton of 1)

IV=intravenous

MAINTENANCE

Only 6 SC Doses
Per Year

(360 mg/2.4 mL per dose)

MAINTENANCE: Only 6 SC Doses Per Year Week 12, 20, 28, 36, 44 and 52

On-Body Injector (OBI) with SKYRIZI
prefilled cartridge for SC injection

NDC Code: 0‍0‍7‍4‍-1070-‍0‍1 (Kit)

SC=subcutaneous

ADMINISTRATION CONSIDERATIONS: SKYRIZI is intended for use under the guidance and supervision of a healthcare professional (HCP). SKYRIZI vial for intravenous administration is intended for administration by an HCP. Prior to starting therapy, please refer to the Dosage and Administration section of the Prescribing Information for complete information on how to initiate, prepare, and administer SKYRIZI. Patients may self-inject SKYRIZI using the on‑body injector with prefilled cartridge after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1

Lab Monitoring

Treatment Considerations in Crohn's Disease1

Infections: SKYRIZI may increase the risk of infections. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If such an infection develops, monitor the patient closely and do not administer SKYRIZI until the infection resolves.

Tuberculosis (TB): Evaluate for TB infection prior to initiating treatment with SKYRIZI.

Vaccinations: Complete all age-appropriate vaccinations according to current immunization guidelines prior to initiating treatment with SKYRIZI.

INTRODUCING THE ON-BODY INJECTOR (OBI) FOR CD PATIENTS

Single-use SC Injector with SKYRIZI Prefilled Cartridge

DESIGNED WITH YOUR PATIENTS IN MIND

COMPACT SIZE

Small enough to fit in the palm of the hand

HANDS-FREE

While adhered to the body and after activation, patients can do moderate physical activities such as walking, reaching and bending

HIDDEN NEEDLE

Discreet injection so patients don't see the needle

DOSE DELIVERED IN 5 MINUTES

Following preparation steps

AUDIO & VISUAL CUES

Notifies when full dose has been delivered

Have you seen this video on
how to inject SKYRIZI using the ON-BODY INJECTOR (OBI)?

The SKYRIZI "Instructions for Use" includes the full set of detailed instructions on the preparation and administration of SKYRIZI. Instruct the patient to read before administration.

5 P's TO HELP YOUR PATIENTS REMEMBER

On-body Injector (OBI) for CD Patients

1 Prepare

Gather alcohol wipes, gauze pads or cotton balls, and sharps disposal container.

2 Pick

Pick a place on the thigh or abdomen to inject.

3 Peel

Peel the 2 green pull tabs to reveal the adhesive without touching the needle.

4 Place

Place the OBI onto the skin. Ensure that the status light is visible.

5 Press

Press and release the gray start button to begin. A flashing green light will appear. When the injection is complete, the green light goes solid.


ADMINISTRATION CONSIDERATIONS: SKYRIZI is intended for use under the guidance and supervision of a healthcare professional (HCP). Patients may self-inject SKYRIZI using the on-body injector with prefilled cartridge after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1

46 patients participated in a questionnaire on their experience using the OBI (interim analysis)2:

93%

(42/45) of patients reported the OBI was “easy to use” or “very easy to use” after the first use.2

DESCRIPTION: In an ongoing open label, two-arm multicenter study evaluating the SKYRIZI On-Body Injector (N=46), interim analysis for patient experience was reported through questions within 6 domains of a validated Self-Injection Assessment Questionnaire (SIAQ). Data includes percent of patients reporting easy/very easy from a single item in the ease-of-use domain after the initial injection at Week 0 of the open-label study. All data reported are as observed. The SKYRIZI OBI was not evaluated in the primary analyses of the Phase 3 Clinical Trials in CD.2

ADMINISTRATION CONSIDERATIONS: SKYRIZI is intended for use under the guidance and supervision of a healthcare professional (HCP). Patients may self-inject SKYRIZI using the on-body injector with prefilled cartridge after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1